Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Burzynski Clinic Presents Over Five Years Survival Data From Phase II Trials of ANP for Inoperable Brain Tumors at the Congress

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/16/2013 | 03:34am CEST

The Burzynski Clinic (BC) announced today that it made a keynote speaker presentation at the 2nd Annual Congress of Asia-Pacific Academy of Anti-Aging Medicine in Beijing, China. Based on the presentation in Beijing, a total of 401 eligible patients (patients who received over 28 days of treatment) with advanced inoperable brain tumors have been treated with antineoplaston A10 and antineoplastons AS2-1 therapy (ANP) in phase II studies. Most of the patients (87%) were diagnosed with high-grade tumors and the remaining patients were diagnosed with low-grade tumors. The patients were diagnosed by pathologists not associated with BC and objective responses were verified by Central Radiology Review. The group of 77 patients (19%) survived over five years from the treatment start. Of particular interest were results in patients with brainstem gliomas. The group of 17 patients with brainstem glioma underwent the treatment and 65% of these patients survived over five years. An additional group of 42 patients diagnosed with diffuse intrinsic pontine glioma (DIPG) have been treated and a total of 19% survived over five years.

The quality of survival is very good and there is no long-term toxicity related to ANP.

These clinical results are very encouraging, since they describe a positive ANP effect on some of the worst malignancies in the entire oncology field, but they will require FDA approval.

Burzynski Clinic is committed to developing treatments for cancer based on genomic and epigenomic principles.

Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to the clinic's ability to use Antineoplastons A10 and AS2-1. Burzynski Clinic does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein.

For Burzynski Clinic
Carolyn Powers, 713-335-5664
carolyn@burzynskiclinic.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
10:32a Kenmare Reports Huge USD50 Million Loss But Expects Better Second Half
10:32aDJASTRAZENECA : Sells Part of its Antibiotics Business to Pfizer -- Update
10:31a PADDY POWER BETFAIR : Upgrades Merger Cost Synergies, Posts Loss
10:31a WPP : Shares Jump As Revenue, Net Sales Rise In First Half
10:31a NORTHROP GRUMMAN : NCTC receives donated drone from Northrop Grumman
10:29a OMV AND VERBUND : Joint projects for the future of energy
10:29a THE 7TH INTERNATIONAL SYMPOSIUM OF ADVANCED ENERGY SCIENCE : Frontiers of Zero Emission Energy
10:29a INTEX RESOURCES : Itx - invitation to q2 results, tuesday 30 august
10:29a DELTA ELECTRONICS : Headquarters Building Receives LEED Platinum Certification from the U.S. Green Building Council
10:29a MONTAN MINING : to Raise up to USD0.57 Million in Private Placement of Units
Latest news
Advertisement
Hot News 
3.62%HEADLAM : UK carpet seller Headlam ups prices after post-Brexit sterling weakness
5.67%WPP : Profit Plunges in First Half
9.86%SVENSKA CELLULOSA : Sweden's SCA Plans Separate Listing for Its Two Divisions
-2.18%WESFARMERS : Net Profit Falls on Writedowns
10.16%ONESAVINGS BANK : more keen on lending to professional landlords after Brexit
Most Read News
08/23 SOLARCITY : Tesla touts speed and driving range with new upgraded battery
04:20a Top SABMiller shareholder Aberdeen backs court ruling on AB InBev deal
01:01a Samsung, Tencent surge in race to become Asia's most valuable firm
02:53a GLENCORE : underlying profit falls, lowers debt target
08/23 VOLKSWAGEN : Lamborghini sees worldwide sales doubling by 2019 after SUV launch
Most recommended articles
04:32aDJASTRAZENECA : Sells Part of its Antibiotics Business to Pfizer -- Update
04:20a Top SABMiller shareholder Aberdeen backs court ruling on AB InBev deal
04:17a HEADLAM : UK carpet seller Headlam ups prices after post-Brexit sterling weakness
04:15aDJGlencore Reports Narrower Loss, Cuts Debt
04:15aDJWPP : Shares Lifted by Sales Growth